
Conference Coverage
Latest Content

FAQ: Measles

VAX-31 Meets Primary Endpoints in Phase 3 Pneumococcal Vaccine Study

Long-Acting Cabotegravir/Rilpivirine Superior to Daily Oral ART for HIV

From Pathogen to Infectious Disease Diagnosis: Multispecies Immunoblot Nearly Doubles Early Lyme Disease Detection

Russian Lab Worker Dies in Suspected Pneumonic Plague Case

Shorts










Contagion Digital Edition









All News

A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.

Recent urinary tract infection guideline updates from multiple international medical societies highlight evolving recommendations, including a major shift in classification, moving from anatomy- and risk factor–based definitions toward distinguishing localized from systemic infections.

A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.

The latest CDC numbers show a 6.2% increase of measles cases from week-to-week. Last week there was a 5.4% increase in cases showing a continuing steady increase dictated by ongoing outbreaks across the US.

Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.

IDSA/ESCMID panel member Henry Chambers, MD, explains why the new S aureus bacteremia guidance replaces the complicated vs uncomplicated label with risk stratification, and how the statements are akin to the stages of cancer in guiding treatment decisions associated with this bacteremia.

Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.

Following World Rabies Day and a CDC health advisory on a 17% rise in exposure-related calls, Rodney E. Rohde, PhD, explains what the increase means, what people should do when they have an animal bite or scratch, and how clinicians should assess risk and administer post-exposure prophylaxis (PEP).

In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.

The monoclonal antibody, Brelovitug, met the combined virologic and ALT response end point at week 24 in AZURE-1, with 56% response on 300 mg weekly and 45% on 900 mg every four weeks. The manufacturer projects a potential US launch in the fourth quarter of 2027.

Staphylococcus aureus Bacteremia (SAB) causes significant morbidity and globally is the leading cause of death from bloodstream infection. This month, the IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.

With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.

The federal agency is investigating four active outbreaks linked to food and animal contact.

Widespread antimicrobial use disrupts vital microbial communities that regulate Earth’s biogeochemical cycles, driving antimicrobial resistance, worsening human and environmental health, and significantly contributing to climate change.

The latest CDC numbers show a 5.4% increase of measles cases from week-to-week. This year has already become the worst for the number of measles cases in the US since the disease was declared eliminated in 2000. With the start of respiratory virus season, case numbers are expected to continue to increase significantly.































































































































































































